Medical Therapy. Adverse Effects or Lack of Adverse Effects

Macitentan: Pediatric First Approval

Susan J. KeamSpringer Nature.New Zealand Paediatric DrugsPaediatr Drugs 2025; DOI: 10.1007/s40272-025-00692-8 AbstractMacitentan (Opsumit®), an endothelin receptor antagonist (ERA) developed by Johnson & Johnson, is well established worldwide as monotherapy or combination therapy for the long-term treatment of pulmonary arterial hypertension (PAH). In September 2024, based on phase 3 clinical data in patients aged < 18 years, […]

Macitentan: Pediatric First Approval Read More »

Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery

Jin Shentu, Mingjie Zhang, Zhuoming Xu, Chen Wen, Hao Zhang, Zhongqun Zhu, Huiwen Chen, Guocheng ShiShanghai Children’s Medical Center and Shanghai Jiao Tong University. China Journal of the American Heart AssociationJ Am Heart Assoc 2025; 14: DOI: 10.1161/JAHA.124.036911 AbstractBackground: Recurrent pulmonary vein stenosis (PVS) following surgical repair of total anomalous pulmonary venous connection is associated with poor prognosis. Preclinical studies have shown that use of an angiotensin receptor blocker can attenuate intimal

Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery Read More »

Inhaled Epoprostenol in Children With Pediatric Acute Respiratory Distress Syndrome: A Single-Center Retrospective Study

Eleanor J. Scalone, Alan G. Woodruff, Amit K. Saha, John M. Wright, Kristopher L. Dixon, Andora L. Bass, Michael J. Walsh, Michael C. McCroryWake Forest University School of Medicine. University of Pennsylvania Perelman School of Medicine.United States Pediatric PulmonologyPediatr Pulmonol 2025; 60: DOI: 10.1002/ppul.71010 AbstractBackground: Inhaled epoprostenol (iEpo) may improve oxygenation in adults with hypoxic respiratory failure,

Inhaled Epoprostenol in Children With Pediatric Acute Respiratory Distress Syndrome: A Single-Center Retrospective Study Read More »

Bosentan as adjunctive therapy in neonates with congenital diaphragmatic hernia-associated pulmonary hypertension: a case series

Aster De Vadder, Lotte Lemloh, Bartolomeo Bo, Lennart Hale, Neil Patel, Andreas Mueller, Florian KipfmuellerChildren’s Hospital, University of Bonn. Royal Hospital for Children. Germany and United Kingdom European Journal of PediatricsEur J Pediatr 2025; 184: DOI: 10.1007/s00431-025-06019-6 AbstractCongenital diaphragmatic hernia (CDH)-associated pulmonary hypertension (PH) is associated with high morbidity and mortality. Pulmonary vasodilative management is challenging

Bosentan as adjunctive therapy in neonates with congenital diaphragmatic hernia-associated pulmonary hypertension: a case series Read More »

Targeting Lung Heme Iron by Aerosol Hemopexin Administration in Sickle Cell Disease Pulmonary Hypertension

Melissa Lucero, Christina Lisk, Francesca Cendali, Delaney Swindle, Saini Setua, Kiruphagaran Thangaraju, David I. Pak, Quinton O’Boyle, Shuwei Lu, Robert Tolson, Seth Zaeske, Nishant Rana, Saqib Khan, Natalie Westover, Pavel Davizon Castillo, Gemlyn George, Kathryn Hassel, Rachelle Nuss, Nathan Brinkman, Thomas Gentinetta, Andre F. Palmer, Angelo D’Alessandro, Paul W. Buelher, David C. IrwinUniversity of Colorado,

Targeting Lung Heme Iron by Aerosol Hemopexin Administration in Sickle Cell Disease Pulmonary Hypertension Read More »

Amniotic fluid stem cell extracellular vesicles as a novel fetal therapy for pulmonary hypoplasia: a review on mechanisms and translational potential

Fabian Doktor, Lina Antounians, Rebeca Lopes Figueira, Kasra Khalaj, Miriam Duci, Augusto ZaniHospital for Sick Children and University of Toronto. Leipzig University.Canada and Germany Stem Cells Translational MedicineStem Cells Transl Med 2025; 14: DOI: 10.1093/stcltm/szae095 AbstractDisruption of developmental processes affecting the fetal lung leads to pulmonary hypoplasia. Pulmonary hypoplasia results from several conditions including congenital diaphragmatic

Amniotic fluid stem cell extracellular vesicles as a novel fetal therapy for pulmonary hypoplasia: a review on mechanisms and translational potential Read More »

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients – An Open-Label Phase 2 Study

Toru Iwasa, Ryo Inuzuka, Hiroshi Ono, Yuichiro Sugitani, Hirokuni Yamazawa, Chihiro Hiraishi, Naoki Shiota, Shinichi Tanaka, Chieko Yamamoto, Ken-ichi Kurosaki, Masaru Miura, Satoshi YasukochiNational Cerebral and Cardiovascular Center. University of Tokyo. National Center for Child Health and Development. Japan Community Health Care Organization Kyushu Hospital. Hokkaido University. Nippon Shinyaku Company. Tokyo Metropolitan Children’s Medical Center.

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients – An Open-Label Phase 2 Study Read More »

Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age

Shin Kato, Yohei Minamitani, Miku Hosokawa, Toshinori Nakashima, Sota Iwatani, Katsuya Hirata, Arata Oda, Takushi Hanita, Masafumi Miyata, Fumihiko Namba, Masayuki Ochiai, Atsushi Nakao, Seiji Yoshimoto, Daichi Suzuki, Erika Ota, Hidehiko Nakanishi, on behalf of the Japan Society for Neonatal Health and DevelopmentJapanese Red Cross Aichi Medical Center Nagoya Daini Hospital. Saitama Medical Center and

Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age Read More »

Sotatercept: A New Era in Pulmonary Arterial Hypertension

Suneesh C. Anand, Muhammad Furqan, Adriano R. Tonelli, Daniela Brady, Avi Levine, Erika B. Rosenzweig, William H. Frishman, Wilbert S. Aronow, Gregg M. LanierHillcrest Hospital and Cleveland Clinic. New York Medical College, Maria Fareri Children’s Hospital of Westchester and  Westchester Medical Center.United States Cardiology in ReviewCardiol Rev 2025; DOI: 10.1097/CRD.0000000000000837 AbstractPulmonary arterial hypertension (PAH) is a

Sotatercept: A New Era in Pulmonary Arterial Hypertension Read More »

Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension

Cara Morgan, Nikmah Idris, Kathy Elterefi, Luca Di Ienno, Andrew Constantine, Sadia Quyam Roberta Bini, Shahin MoledinaGreat Ormond Street Hospital for Children. Queen Elizabeth Hospital. Institute of Cardiovascular Sciences University College London. United Kingdom Pulmonary CirculationPulm Circ 2024;DOI: 10.1002/pul2.70011 AbstractThe aim of this single-centre retrospective observational study was to evaluate the safety, tolerability, and efficacy of

Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension Read More »

Scroll to Top